



## bioMérieux to present at the 43<sup>rd</sup> Annual J.P. Morgan HealthCare Conference

**Marcy l'Étoile, France, January 13, 2025** – bioMérieux, a world leader in the field *in vitro* diagnostics, today announces its participation in the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, USA, from January 13 to 16, 2025.

Pierre Boulud, Chief Executive Officer of bioMérieux, will give a presentation on January 14, 2025, at 5:15 pm PT (02:15 am CET). A Q&A session will follow the presentation.

On this occasion, Pierre Boulud, will present an overview of bioMérieux together with the main drivers of its strategic plan, GO•28, presented last April, during the Capital Markets Day. The ambition is to deliver a profitable and sustainable growth with a +7% CAGR<sup>1</sup> organic sales growth over the period 2024 / 2028 and an increase in CEBIT<sup>2</sup> margin from 16.6% of sales in 2023 to 20% in 2028 at constant exchange rates and perimeter.

In addition, Pierre Boulud will provide an update on installations of BIOFIRE® and SPOTFIRE® in Q4 2024, respectively +500 net units and +900 units, and present bioMérieux's recent acquisition of SpinChip, a Norwegian start-up dedicated to point-of-care immunoassays.

bioMérieux's presentation (in English) will be broadcasted live (audio only) using the following link: [https://jpmorgan.metameetings.net/events/healthcare25/sessions/58370-biomerieux/webcast?gpu\\_only=true&kiosk=true](https://jpmorgan.metameetings.net/events/healthcare25/sessions/58370-biomerieux/webcast?gpu_only=true&kiosk=true)

The slides of the presentation will be made available on the company's website: [www.biomerieux.com](http://www.biomerieux.com).

### INVESTOR CALENDAR

Fourth-quarter 2024 sales and 2024 financial results

March, 7<sup>th</sup> 2025

---

<sup>1</sup> CAGR: Compound Annual Growth Rate

<sup>2</sup> CEBIT: Contributive operating income before non-recurring items: operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs.



## ABOUT BIOMÉRIEUX

### *Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 93% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: [www.biomerieux.com](http://www.biomerieux.com)

## CONTACTS

### INVESTORS RELATIONS

Aymeric Fichet

Tel.: +33 (0)4 78 87 20 00

[investor.relations@biomerieux.com](mailto:investor.relations@biomerieux.com)

### MEDIA RELATIONS

#### CORPORATE

Romain Duchez

Tel.: +33 (0)4 78 87 20 00

[media@biomerieux.com](mailto:media@biomerieux.com)

#### UNITED STATES

Liza Deckelbaum (SEEZ)

Tel. : (919) 521-0507

[lizad@seeztoday.com](mailto:lizad@seeztoday.com)

#### FRANCE

Laurence Heilbronn (Image 7)

Tel.: +33 (0)1 53 70 74 48

[lheilbronn@image7.fr](mailto:lheilbronn@image7.fr)

PRESS RELEASE